Abstract
Delgocitinib is a novel Janus kinase（JAK） inhibitor discovered by Japan Tobacco Inc. based on its inhibitory activity against human JAK1, JAK2, JAK3, and tyrosine kinase 2. CORECTIMⓇ Ointment 0.5％ containing Delgocitinib was launched as a topical JAK inhibitor for the first time in the world in June 2020, and 0.25％ Ointment was launched in the following year. In the formulation of CORECTIMⓇ Ointment, the physicochemical stability of drug substance, the physical property evaluation of the ointment, sensuality and stability evaluation were performed, and it was necessary to develop a formulation with excellent usability and stability. The development history, formulation development, pharmacokinetics, and clinical study results of CORECTIMⓇ Ointment are also described here.
